• Event-free survival rate [ Designated as safety issue: No ]
  
• Response after induction therapy [ Designated as safety issue: No ]
  
• Incidence rate of local recurrence [ Designated as safety issue: No ]
  

• Duration of ≥ grade 3 neutropenia during course one [ Designated as safety issue: No ]
  
• Duration of ≥ grade 3 thrombocytopenia during course one [ Designated as safety issue: No ]
  
• Response rate after two courses of induction therapy [ Designated as safety issue: No ]
  

DISEASE CHARACTERISTICS:

• Diagnosis of neuroblastoma or ganglioneuroblastoma by histology or as evidenced by the presence of clumps of tumor cells in bone marrow and elevated catecholamine metabolites in urine meeting any of the following criteria:

  • Patients with newly diagnosed neuroblastoma with International Neuroblastoma Staging System (INSS) stage 4 disease are eligible with the following:

    • MYCN amplification (i.e., greater than four-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features
    • Age > 18 months (i.e., > 547 days) regardless of biologic features
    • Age 12-18 months (i.e., 365-547 days) with any of the following three unfavorable biologic features (i.e., MYCN amplification, unfavorable pathology, and/or DNA index = 1) or any biologic feature that is indeterminant, unsatisfactory, or unknown

  • Patients with newly diagnosed neuroblastoma with INSS stage 3 are eligible with the following:

    • MYCN amplification (i.e., greater than four-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features
    • Age > 18 months (i.e., > 547 days) with unfavorable pathology, regardless of MYCN status
  • Patients with newly diagnosed INSS stage 2a or 2b with MYCN amplification (i.e., greater than four-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features
  • Patients with newly diagnosed INSS stage 4s with MYCN amplification (i.e., greater than four-fold increase in MYCN signals as compared to reference signals), regardless of additional biologic features

  • Patients ≥ 365 days initially diagnosed with INSS stage 1, 2, or 4S and who progressed to a stage 4 without interval chemotherapy

    • Must have been enrolled on COG-ANBL00B1

PATIENT CHARACTERISTICS:

• Creatinine clearance or radioisotope glomerular filtration rate ≥ 70mL/min OR serum creatinine based on age/gender as follows:

  • 1 month to < 6 months: 0.4 mg/dL
  • 6 months to < 1 year: 0.5 mg/dL
  • 1 to < 2 years: 0.6 mg/dL
  • 2 to < 6 years: 0.8 mg/dL
  • 6 to < 10 years: 1 mg/dL
  • 10 to < 13 years: 1.2 mg/dL
  • 10 to < 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)
  • ≥ 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
• AST or ALT < 10 times ULN for age
• Shortening fraction ≥ 27% by ECHO OR LVEF ≥ 50% by radionuclide angiogram
• No known contraindication (e.g., size, weight or physical condition) to peripheral blood stem cell collection

PRIOR CONCURRENT THERAPY:

• No prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease
• No more than one course of chemotherapy per low- or intermediate-risk neuroblastoma therapy prior to determination of MYCN amplification and histology